Calidi Biotherapeutics, Inc.
New York Stock Exchange ArcaTotal Valuation
Calidi Biotherapeutics, Inc. carries a market capitalization of 1.97M, placing it among publicly traded companies globally. Its enterprise value stands at -1.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.97M |
| Enterprise Value | -1.64M |
Share Statistics
Calidi Biotherapeutics, Inc. currently has 179,812.00 shares outstanding.
| Shares Outstanding | 179,812.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | -0.12 |
| P/OCF Ratio | -0.12 |
Financial Position
Calidi Biotherapeutics, Inc. maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.99, indicating elevated leverage, while an interest coverage ratio of -103.44 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.68 |
| Quick Ratio | 1.34 |
| Debt / Equity | 61.99 |
| Debt / EBITDA | -0.12 |
| Interest Coverage | -103.44 |
Financial Efficiency
| Return on Equity (ROE) | -713.62 |
| Return on Assets (ROA) | -211.09 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 17,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Calidi Biotherapeutics, Inc.'s stock has declined approximately -97.02461% over the past 52 weeks. The 50-day moving average sits at 1.21, while the 200-day moving average is 5.23.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.02461% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 5.23 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -16.14M, while operating income came in at -17.85M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -17.85M |
| Pretax Income | -17.49M |
| Net Income | -17.47M |
| EBITDA | -16.14M |
| EBIT | -17.85M |
| Earnings Per Share (EPS) | -22.19 |
Balance Sheet
Calidi Biotherapeutics, Inc. holds 4.07M in cash and equivalents against 1.94M in total debt, resulting in a net debt position of -3.47M. Total book value stands at 3.13M, with working capital of 2.19M providing operational flexibility.
| Cash & Cash Equivalents | 4.07M |
| Total Debt | 1.94M |
| Net Debt | -3.47M |
| Equity (Book Value) | 3.13M |
| Book Value Per Share | 17.42 |
| Working Capital | 2.19M |
Cash Flow
Calidi Biotherapeutics, Inc. produced -17.75M in operating cash flow over the past twelve months. After subtracting -94,000.00 in capital expenditures, free cash flow totaled -17.84M - equivalent to -22.62 per share.
| Operating Cash Flow | -17.75M |
| Capital Expenditures | -94,000.00 |
| Free Cash Flow | -17.84M |
| FCF Per Share | -22.62 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3,436.60 |
| FCF Yield | -822.78 |
Stock Splits
Calidi Biotherapeutics, Inc.'s most recent stock split took place on July 31, 2026 with a 16:1 split ratio.
| Last Split Date | 7/31/2026 |
| Split Ratio | 16:1 |
Scores
Calidi Biotherapeutics, Inc. posts an Altman Z-Score of -36.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -36.87 |